Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
31 hedge funds and large institutions have $4.84M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 6 closing their positions.
291% more call options, than puts
Call options by funds: $1.54M | Put options by funds: $394K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 33 → 31 (-2)
6% less capital invested
Capital invested by funds: $5.17M → $4.84M (-$331K)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.13M |
| 2 |
Morgan Stanley
New York
|
+$122K |
| 3 |
State Street
Boston,
Massachusetts
|
+$113K |
| 4 |
Millennium Management
New York
|
+$46.4K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$36.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
-$260K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$158K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$151K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$99.9K |
| 5 |
Jane Street
New York
|
-$78K |
NBRV Hedge Fund Activity: Q2 2021 in Review
31 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q2 2021, worth a combined $4.84M — down 6.4% from $5.17M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NBRV and 4 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.13M. The largest seller was Squarepoint, exiting entirely with an estimated $260K sold.
- 31 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q2 2021, down from 33 in Q1 2021.
- Funds reported $4.84M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q2 2021, down 6.4% quarter-over-quarter.
- 4 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q2 2021 and 6 closed out, a net change of -2 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q2 2021 was Renaissance Technologies, an estimated $1.13M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q2 2021 was Squarepoint, an estimated $260K sold.
Based on aggregated 13F filings for Q2 2021.